BioNTech Phase 3 trial of variant-adapted BNT162b2 COVID vaccine recruitingSep 30Weekly roundup, 7 itemsatirmociclibberobenatide
Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drugAug 4Quarterly updateArvinas Inc.
Rigel adds VEPPANU to portfolio, keeps R289 timeline, raises 2026 revenue guidanceAug 4Quarterly updateRigel Pharmaceuticals Incvepdegestrant
Sign inSign in